Search results
Here, we assess the relationship between early reported side effects and incidence of breast cancer in women randomised to tamoxifen for cancer prevention in the International Breast Intervention Study (IBIS)–I trial.
- Tamoxifen - StatPearls - NCBI Bookshelf - National Center for ...
Like many cancer drugs, tamoxifen has many adverse effects...
- Tamoxifen side effects: pharmacogenetic and clinical approach in ...
Results. Hot flashes (57.75%), arthralgia (45.07%), headache...
- Clinical and biomarker predictors of side effects from tamoxifen
Common tamoxifen attributed side effects were hot flashes...
- Tamoxifen related side effects and their impact on breast ... - PubMed
Here, we assess the relationship between early reported side...
- Tamoxifen - StatPearls - NCBI Bookshelf - National Center for ...
10 kwi 2023 · Like many cancer drugs, tamoxifen has many adverse effects associated with it, though serious and fatal ones are rare. The most common adverse effects seen in treatment are hot flashes, irregular periods, and vaginal discharge.
27 gru 2018 · Results. Hot flashes (57.75%), arthralgia (45.07%), headache (43.66%), and cramps (39.44%) were the most frequent TSE. Three GP were identified: gPM (2.8%); gNM (93.0%); and gUM (4.2%). In the univariate analysis, none of the GP was predictive of TSE.
Common tamoxifen attributed side effects were hot flashes (64%), vaginal dryness (35%), sleep problems (36%), weight gain (6%), and depression, irritability or mood swings (6%). In multi-variate models, tamoxifen duration, age, prior post-menopausal hormone therapy, and endoxifen levels all predicted side effects.
However, tamoxifen users may experience adverse effects of the medication. For example, tamoxifen increases the risk of gynaecological and vasomotor symptoms, thromboembolic events and endometrial cancer (5,7–9). The majority of side-effects start within 12-months of initiation, but can occur throughout treatment (7,8).
Here, we assess the relationship between early reported side effects and incidence of breast cancer in women randomised to tamoxifen for cancer prevention in the International Breast Intervention Study (IBIS)-I trial.
Common tamoxifen attributed side effects were hot flashes (64%), vaginal dryness (35%), sleep problems (36%), weight gain (6%), and depression, irritability or mood swings (6%). In multi-variate models, tamoxifen duration, age, prior post-menopausal HT, and endoxifen levels all predicted side effects.
